KYNB
KYNB
NASDAQ · Biotechnology

Kyntra Bio Inc

$7.55
+0.24 (+3.28%)
As of Jun 30, 10:44 PM ET ·
Financial Highlights (FY 2026)
Revenue
6.18M
Net Income
176.07M
Gross Margin
91.4%
Profit Margin
2,848.6%
Rev Growth
-64.2%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 91.4% 91.4% 66.4% 66.4%
Operating Margin -814.9% -733.4% -24.8% -27.2%
Profit Margin 2,848.6% 2,706.2% -23.6% -26.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 6.18M 17.28M 5.44M 5.56M
Gross Profit 5.65M 15.79M 3.61M 3.69M
Operating Income -50,368,099 -126,729,910 -1,347,007 -1,515,511
Net Income 176.07M 443.01M -1,283,535 -1,495,769
Gross Margin 91.4% 91.4% 66.4% 66.4%
Operating Margin -814.9% -733.4% -24.8% -27.2%
Profit Margin 2,848.6% 2,706.2% -23.6% -26.9%
Rev Growth -64.2% -64.2% +18.0% +2.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.09M 1.09M 11.14M 12.70M
Total Equity 12.96M 12.96M 24.70M 26.50M
D/E Ratio 0.08 0.08 0.45 0.48
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -49,649,366 -131,861,609 -2,024,078 -1,912,875
Free Cash Flow -1,099,827 -902,858